Search

Your search keyword '"Lotze, Michael T"' showing total 464 results
Start Over Author "Lotze, Michael T" Publication Year Range Last 10 years
464 results on '"Lotze, Michael T"'

2. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee

Author

Gastman, Brian, Agarwal, Piyush K, Berger, Adam, Boland, Genevieve, Broderick, Stephen, Butterfield, Lisa H, Byrd, David, Fecci, Peter E, Ferris, Robert L, Fong, Yuman, Goff, Stephanie L, Grabowski, Matthew M, Ito, Fumito, Lim, Michael, Lotze, Michael T, Mahdi, Haider, Malafa, Mokenge, Morris, Carol D, Murthy, Pranav, Neves, Rogerio I, Odunsi, Adekunle, Pai, Sara I, Prabhakaran, Sangeetha, Rosenberg, Steven A, Saoud, Ragheed, Sethuraman, Jyothi, Skitzki, Joseph, Slingluff, Craig L, Sondak, Vernon K, Sunwoo, John B, Turcotte, Simon, Yeung, Cecilia CS, and Kaufman, Howard L

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Immunization, Rare Diseases, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Orphan Drug, Detection, screening and diagnosis, 4.5 Resources and infrastructure (detection), Good Health and Well Being, Clinical Trials as Topic, Humans, Immunotherapy, Medical Oncology, Tissue and Organ Procurement, biomarkers, tumor, guidelines as topic, review, clinical trials as topic, immunotherapy, Oncology and carcinogenesis
Abstract

Immunotherapy is now a cornerstone for cancer treatment, and much attention has been placed on the identification of prognostic and predictive biomarkers. The success of biomarker development is dependent on accurate and timely collection of biospecimens and high-quality processing, storage and shipping. Tumors are also increasingly used as source material for the generation of therapeutic T cells. There have been few guidelines or consensus statements on how to optimally collect and manage biospecimens and source material being used for immunotherapy and related research. The Society for Immunotherapy of Cancer Surgery Committee has brought together surgical experts from multiple subspecialty disciplines to identify best practices and to provide consensus on how best to access and manage specific tissues for immuno-oncology treatments and clinical investigation. In addition, the committee recommends early integration of surgeons and other interventional physicians with expertise in biospecimen collection, especially in clinical trials, to optimize the quality of tissue and the validity of correlative clinical studies in cancer immunotherapy.

Published
2020

3. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

Author

Galluzzi, Lorenzo, Vitale, Ilio, Warren, Sarah, Adjemian, Sandy, Agostinis, Patrizia, Martinez, Aitziber Buqué, Chan, Timothy A, Coukos, George, Demaria, Sandra, Deutsch, Eric, Draganov, Dobrin, Edelson, Richard L, Formenti, Silvia C, Fucikova, Jitka, Gabriele, Lucia, Gaipl, Udo S, Gameiro, Sofia R, Garg, Abhishek D, Golden, Encouse, Han, Jian, Harrington, Kevin J, Hemminki, Akseli, Hodge, James W, Hossain, Dewan Md Sakib, Illidge, Tim, Karin, Michael, Kaufman, Howard L, Kepp, Oliver, Kroemer, Guido, Lasarte, Juan Jose, Loi, Sherene, Lotze, Michael T, Manic, Gwenola, Merghoub, Taha, Melcher, Alan A, Mossman, Karen L, Prosper, Felipe, Rekdal, Øystein, Rescigno, Maria, Riganti, Chiara, Sistigu, Antonella, Smyth, Mark J, Spisek, Radek, Stagg, John, Strauss, Bryan E, Tang, Daolin, Tatsuno, Kazuki, van Gool, Stefaan W, Vandenabeele, Peter, Yamazaki, Takahiro, Zamarin, Dmitriy, Zitvogel, Laurence, Cesano, Alessandra, and Marincola, Francesco M

Subjects
Inflammatory and immune system, Consensus, Guidelines as Topic, Humans, Immunogenic Cell Death, Molecular Biology, oncology, immunology, molecular biology
Abstract

Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. Here, we provide an updated operational definition of immunogenic cell death (ICD), discuss the key factors that dictate the ability of dying cells to drive an adaptive immune response, summarize experimental assays that are currently available for the assessment of ICD in vitro and in vivo, and formulate guidelines for their interpretation.

Published
2020

4. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Author

Bedognetti, Davide, Ceccarelli, Michele, Galluzzi, Lorenzo, Lu, Rongze, Palucka, Karolina, Samayoa, Josue, Spranger, Stefani, Warren, Sarah, Wong, Kwok-Kin, Ziv, Elad, Chowell, Diego, Coussens, Lisa M, De Carvalho, Daniel D, DeNardo, David G, Galon, Jérôme, Kaufman, Howard L, Kirchhoff, Tomas, Lotze, Michael T, Luke, Jason J, Minn, Andy J, Politi, Katerina, Shultz, Leonard D, Simon, Richard, Thórsson, Vésteinn, Weidhaas, Joanne B, Ascierto, Maria Libera, Ascierto, Paolo Antonio, Barnes, James M, Barsan, Valentin, Bommareddy, Praveen K, Bot, Adrian, Church, Sarah E, Ciliberto, Gennaro, De Maria, Andrea, Draganov, Dobrin, Ho, Winson S, McGee, Heather M, Monette, Anne, Murphy, Joseph F, Nisticò, Paola, Park, Wungki, Patel, Maulik, Quigley, Michael, Radvanyi, Laszlo, Raftopoulos, Harry, Rudqvist, Nils-Petter, Snyder, Alexandra, Sweis, Randy F, Valpione, Sara, Zappasodi, Roberta, Butterfield, Lisa H, Disis, Mary L, Fox, Bernard A, Cesano, Alessandra, and Marincola, Francesco M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Women's Health, Genetics, Cancer, Human Genome, Underpinning research, 1.1 Normal biological development and functioning, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Advisory Committees, Animals, Biomarkers, Tumor, Congresses as Topic, Disease Models, Animal, Humans, Immunotherapy, Medical Oncology, Neoplasms, Societies, Medical, Treatment Outcome, Tumor Microenvironment, Cancer immune responsiveness, Immune checkpoint inhibitor, Immune oncology, Tumor microenvironment, Tumor mutational burden, Immunogenic cell death, Biomarker, Germline molecular alterations, Somatic molecular alterations, Cancer immune phenotype, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Oncology and carcinogenesis
Abstract

Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR include the genetic makeup of the patient, the genomic instability central to cancer development, the evolutionary emergence of cancer phenotypes under the influence of immune editing, and external modifiers such as demographics, environment, treatment potency, co-morbidities and cancer-independent alterations including immune homeostasis and polymorphisms in the major and minor histocompatibility molecules, cytokines, and chemokines. Based on the premise that cancer is fundamentally a disorder of the genes arising within a cell biologic process, whose deviations from normality determine the rules of engagement with the host's response, the Society for Immunotherapy of Cancer (SITC) convened a task force of experts from various disciplines including, immunology, oncology, biophysics, structural biology, molecular and cellular biology, genetics, and bioinformatics to address the complexity of CIR from a holistic view. The task force was launched by a workshop held in San Francisco on May 14-15, 2018 aimed at two preeminent goals: 1) to identify the fundamental questions related to CIR and 2) to create an interactive community of experts that could guide scientific and research priorities by forming a logical progression supported by multiple perspectives to uncover mechanisms of CIR. This workshop was a first step toward a second meeting where the focus would be to address the actionability of some of the questions identified by working groups. In this event, five working groups aimed at defining a path to test hypotheses according to their relevance to human cancer and identifying experimental models closest to human biology, which include: 1) Germline-Genetic, 2) Somatic-Genetic and 3) Genomic-Transcriptional contributions to CIR, 4) Determinant(s) of Immunogenic Cell Death that modulate CIR, and 5) Experimental Models that best represent CIR and its conversion to an immune responsive state. This manuscript summarizes the contributions from each group and should be considered as a first milestone in the path toward a more contemporary understanding of CIR. We appreciate that this effort is far from comprehensive and that other relevant aspects related to CIR such as the microbiome, the individual's recombined T cell and B cell receptors, and the metabolic status of cancer and immune cells were not fully included. These and other important factors will be included in future activities of the taskforce. The taskforce will focus on prioritization and specific actionable approach to answer the identified questions and implementing the collaborations in the follow-up workshop, which will be held in Houston on September 4-5, 2019.

Published
2019

5. Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Author

Bedognetti, Davide, Ceccarelli, Michele, Galluzzi, Lorenzo, Lu, Rongze, Palucka, Karolina, Samayoa, Josue, Spranger, Stefani, Warren, Sarah, Wong, Kwok-Kin, Ziv, Elad, Chowell, Diego, Coussens, Lisa M, De Carvalho, Daniel D, DeNardo, David G, Galon, Jérôme, Kaufman, Howard L, Kirchhoff, Tomas, Lotze, Michael T, Luke, Jason J, Minn, Andy J, Politi, Katerina, Shultz, Leonard D, Simon, Richard, Thórsson, Vésteinn, Weidhaas, Joanne B, Ascierto, Maria Libera, Ascierto, Paolo Antonio, Barnes, James M, Barsan, Valentin, Bommareddy, Praveen K, Bot, Adrian, Church, Sarah E, Ciliberto, Gennaro, De Maria, Andrea, Draganov, Dobrin, Ho, Winson S, McGee, Heather M, Monette, Anne, Murphy, Joseph F, Nisticò, Paola, Park, Wungki, Patel, Maulik, Quigley, Michael, Radvanyi, Laszlo, Raftopoulos, Harry, Rudqvist, Nils-Petter, Snyder, Alexandra, Sweis, Randy F, Valpione, Sara, Zappasodi, Roberta, Butterfield, Lisa H, Disis, Mary L, Fox, Bernard A, Cesano, Alessandra, and Marincola, Francesco M

Subjects
Biomedical and Clinical Sciences, Immunology, Cancer, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Oncology and carcinogenesis
Abstract

Following publication of the original article [1], the author reported that an author name, Roberta Zappasodi, was missed in the authorship list.

Published
2019

7. Cellular Therapy for Melanoma

Author

Kammula, Udai S., Lotze, Michael T., Balch, Charles M., editor, Atkins, Michael B., editor, Garbe, Claus, editor, Gershenwald, Jeffrey E., editor, Halpern, Allan C., editor, Kirkwood, John M., editor, McArthur, Grant A., editor, Thompson, John F., editor, and Sober, Arthur J., editor

Published
2020
Full Text
View/download PDF

10. A guideline on the molecular ecosystem regulating ferroptosis

Author

Dai, Enyong, Chen, Xin, Linkermann, Andreas, Jiang, Xuejun, Kang, Rui, Kagan, Valerian E., Bayir, Hülya, Yang, Wan Seok, Garcia-Saez, Ana J., Ioannou, Maria S., Janowitz, Tobias, Ran, Qitao, Gu, Wei, Gan, Boyi, Krysko, Dmitri V., Zhu, Xiaofeng, Wang, Jiayi, Krautwald, Stefan, Toyokuni, Shinya, Xie, Yangchun, Greten, Florian R., Yi, Qing, Schick, Joel, Liu, Jiao, Gabrilovich, Dmitry I., Liu, Jinbao, Zeh, Herbert J., Zhang, Donna D., Yang, Minghua, Iovanna, Juan, Kopf, Manfred, Adolph, Timon E., Chi, Jen-Tsan, Li, Changfeng, Ichijo, Hidenori, Karin, Michael, Sankaran, Vijay G., Zou, Weiping, Galluzzi, Lorenzo, Bush, Ashley I., Li, Binghui, Melino, Gerry, Baehrecke, Eric H., Lotze, Michael T., Klionsky, Daniel J., Stockwell, Brent R., Kroemer, Guido, and Tang, Daolin

Abstract

Ferroptosis, an intricately regulated form of cell death characterized by uncontrolled lipid peroxidation, has garnered substantial interest since this term was first coined in 2012. Recent years have witnessed remarkable progress in elucidating the detailed molecular mechanisms that govern ferroptosis induction and defence, with particular emphasis on the roles of heterogeneity and plasticity. In this Review, we discuss the molecular ecosystem of ferroptosis, with implications that may inform and enable safe and effective therapeutic strategies across a broad spectrum of diseases.

Published
2024
Full Text
View/download PDF

20. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer

Author

Murthy, Pranav, primary, Zenati, Mazen S., additional, AlMasri, Samer S., additional, DeSilva, Annissa, additional, Singhi, Aatur D., additional, Paniccia, Alessandro, additional, Lee, Kenneth K., additional, Simmons, Richard L., additional, Bahary, Nathan, additional, Lotze, Michael T., additional, and Zureikat, Amer H., additional

Published
2023
Full Text
View/download PDF

23. Consensus nomenclature for CD8+ T cell phenotypes in cancer

Author

Apetoh, Lionel, Smyth, Mark J, Drake, Charles G, Abastado, Jean-Pierre, Apte, Ron N, Ayyoub, Maha, Blay, Jean-Yves, Bonneville, Marc, Butterfield, Lisa H, Caignard, Anne, Castelli, Chiara, Cavallo, Federica, Celis, Esteban, Chen, Lieping, Colombo, Mario P, Comin-Anduix, Begoña, Coukos, Georges, Dhodapkar, Madhav V, Dranoff, Glenn, Frazer, Ian H, Fridman, Wolf-Hervé, Gabrilovich, Dmitry I, Gilboa, Eli, Gnjatic, Sacha, Jäger, Dirk, Kalinski, Pawel, Kaufman, Howard L, Kiessling, Rolf, Kirkwood, John, Knuth, Alexander, Liblau, Roland, Lotze, Michael T, Lugli, Enrico, Marincola, Francesco, Melero, Ignacio, Melief, Cornelis J, Mempel, Thorsten R, Mittendorf, Elizabeth A, Odun, Kunle, Overwijk, Willem W, Palucka, Anna Karolina, Parmiani, Giorgio, Ribas, Antoni, Romero, Pedro, Schreiber, Robert D, Schuler, Gerold, Srivastava, Pramod K, Tartour, Eric, Valmori, Danila, van der Burg, Sjoerd H, van der Bruggen, Pierre, van den Eynde, Benoît J, Wang, Ena, Zou, Weiping, Whiteside, Theresa L, Speiser, Daniel E, Pardoll, Drew M, Restifo, Nicholas P, and Anderson, Ana C

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, 2.1 Biological and endogenous factors, Aetiology, anergy, anticancer immunity, CD8(+) T cells, cytotoxicity, exhaustion, effector, IFN gamma, senescence, stemness, CD8+ T cells, IFNγ, Oncology and carcinogenesis
Abstract

Whereas preclinical investigations and clinical studies have established that CD8+ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8+ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8+ T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8+ T cell immunity, leading to the emergence of dysfunctional CD8+ T cells. The existence of different types of CD8+ T cells in cancer calls for a more precise definition of the CD8+ T cell immune phenotypes in cancer and the abandonment of the generic terms "pro-tumor" and "antitumor." Based on recent studies investigating the functions of CD8+ T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8+ T cells in cancer.

Published
2015

24. Supplementary Table 1 - Gene Expression from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

25. Supp. Figure 2 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

26. Supp. Figure 6 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

27. Data from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

28. Supp. Figure 4 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

29. Supp. Figure 1 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure Legends from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

31. Supp. Figure 3 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

32. Supp. Figure 5 from Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, primary, Mohei, Hesham, primary, Beghi, Silvia, primary, Rivera, Osvaldo D., primary, Kostopoulos, Nektarios, primary, Giglio, Andrea, primary, George, Subin S., primary, Uribe-Herranz, Mireia, primary, Costabile, Francesca, primary, Pierini, Stefano, primary, Pustylnikov, Sergei, primary, Skoufos, Giorgos, primary, Barash, Yoseph, primary, Hatzigeorgiou, Artemis G., primary, Koumenis, Constantinos, primary, Maity, Amit, primary, Lotze, Michael T., primary, and Facciabene, Andrea, primary

Published
2023
Full Text
View/download PDF

39. Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

Author

Perales-Linares, Renzo, primary, Leli, Nektaria Maria, additional, Mohei, Hesham, additional, Beghi, Silvia, additional, Rivera, Osvaldo D., additional, Kostopoulos, Nektarios, additional, Giglio, Andrea, additional, George, Subin S., additional, Uribe-Herranz, Mireia, additional, Costabile, Francesca, additional, Pierini, Stefano, additional, Pustylnikov, Sergei, additional, Skoufos, Giorgos, additional, Barash, Yoseph, additional, Hatzigeorgiou, Artemis G., additional, Koumenis, Constantinos, additional, Maity, Amit, additional, Lotze, Michael T., additional, and Facciabene, Andrea, additional

Published
2023
Full Text
View/download PDF

46. Figure S2 from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression

Author

Tandon, Manuj, primary, Coudriet, Gina M., primary, Criscimanna, Angela, primary, Socorro, Mairobys, primary, Eliliwi, Mouhanned, primary, Singhi, Aatur D., primary, Cruz-Monserrate, Zobeida, primary, Bailey, Peter, primary, Lotze, Michael T., primary, Zeh, Herbert, primary, Hu, Jing, primary, Goffin, Vincent, primary, Gittes, George K., primary, Biankin, Andrew V., primary, and Esni, Farzad, primary

Published
2023
Full Text
View/download PDF

49. Data from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression

Author

Tandon, Manuj, primary, Coudriet, Gina M., primary, Criscimanna, Angela, primary, Socorro, Mairobys, primary, Eliliwi, Mouhanned, primary, Singhi, Aatur D., primary, Cruz-Monserrate, Zobeida, primary, Bailey, Peter, primary, Lotze, Michael T., primary, Zeh, Herbert, primary, Hu, Jing, primary, Goffin, Vincent, primary, Gittes, George K., primary, Biankin, Andrew V., primary, and Esni, Farzad, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Data from A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients

Author

Zeh, Herbert J., primary, Bahary, Nathan, primary, Boone, Brian A., primary, Singhi, Aatur D., primary, Miller-Ocuin, Jennifer Lee, primary, Normolle, Daniel P., primary, Zureikat, Amer H., primary, Hogg, Melissa E., primary, Bartlett, David L., primary, Lee, Kenneth K., primary, Tsung, Allan, primary, Marsh, J. Wallis, primary, Murthy, Pranav, primary, Tang, Daolin, primary, Seiser, Natalie, primary, Amaravadi, Ravi K., primary, Espina, Virginia, primary, Liotta, Lance, primary, and Lotze, Michael T., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results